Lipella Pharmaceuticals 주식 (NASDAQ: LIPO)

에 대한 최신 뉴스 Lipella Pharmaceuticals (NASDAQ:LIPO) 주식

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

Barrington Research analyst Alexander Paris maintains Perdoceo Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) with a Outperform and maintains $32 price target.

News

Price Target

Analyst Ratings

PRDO

Barrington Research Maintains Outperform on Perdoceo Education, Maintains $32 Price Target

Snap Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) CEO, Evan Spiegel, has taken a playful jab at Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) for its history of mimicking Snapchat&#8217;s features in a way that seems to mock the social media giant.
What Happened: Spiegel updated his LinkedIn profile that now read, &#8220;Loving husband, father of four boys, VP Product @ Meta,&#8221; indicates a Fortune <a href="https://fortune.com/2025/02/06/snap-ceo-evan-spiegel-mocks-mark-zuckerberg-meta-copycat-features/">report</a>. This update is widely interpreted as a swipe at Meta&#8217;s penchant for copying Snapchat&#8217;s features.
Despite Mark Zuckerberg&#8216;s&nbsp;$3 billion acquisition offer in&nbsp;2013, Spiegel has staunchly upheld Snap&#8217;s independence. Meta, in turn, has launched features remarkably similar to Snapchat&#8217;s, including Instagram Stories, disappearing direct messages, and face-distorting filters.
Spiegel, in a 2018 conference, shared mixed feelings about Meta&#8217;s imitation, stating, &#8220;It was the best feeling to design something that is so simple and so elegant that the only thing competitors can do is copy it exactly.&#8221; 
He also humorously suggested that Meta should replicate Snapchat&#8217;s data protection practices.
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43527542/meta-stock-soars-but-zuckerbergs-cashing-in-should-investors-worry">Meta Stock Soars, But Zuckerberg&#8217;s Cashing In &#8211; Should Investors Worry?</a>
Why It Matters: A CNBC report in Jan indicated that Meta is providing incentives to creators to advertise Instagram on competing short-form video platforms like TikTok, Snapchat, and YouTube to gain a larger share. This move highlights the intense competition in the social media space, as platforms battle for the attention of millions of users while TikTok&#8217;s future remains uncertain.
Meanwhile, Snap has been grappling with its own challenges. Despite reporting a fourth-quarter <a href="https://www.benzinga.com/25/02/43504595/snap-falls-despite-q4-beat-as-analysts-remain-cautious-on-ad-growth-and-higher-expenses">earnings beat</a>, Snap&#8217;s shares fell as analysts expressed concerns over ad growth and higher expenses.
Last week, Meta announced its fourth-quarter results, surpassing expectations for both revenue and earnings, while reaffirming its commitment to significant AI-related investments.
Snap has a much smaller user base when compared to Meta, but it has posted impressive growth for the fourth quarter. Meta&#8217;s Family Daily Active People (DAP)&nbsp;grew 5.5% year-on-year to 3.35 billion, while Snap&#8217;s Daily Active Users increased 9% year-over-year to 453 million. 
<ul>
<li>READ ALSO: <a href="https://www.benzinga.com/markets/25/02/43552448/pinterests-gen-z-boom-engagement-hits-62-all-time-high-as-advertiser-clicks-surge-90heres-whats-driving-the-growth-for-this-meta-rival">Pinterest&#8217;s Gen Z Boom: Engagement Hits All-Time High As Advertiser Clicks Surge 90%—What&#8217;s Working For The Meta Rival</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

SNAP

Evan Spiegel Takes A Shot At Mark Zuckerberg Over Meta Copying Snapchat's Features On Instagram And Facebook

Guidance

Flowers Foods Sees FY25 Revenue Of $5.403B -$5.487B Vs. $5.22B Est; Adj EPS Of $1.11 - $1.24 Vs. $1.3 Est.

For the&nbsp;first quarter&nbsp;of 2025, Fortive anticipates revenue of&nbsp;$1.48 billion&nbsp;to&nbsp;$1.51 billion, diluted net earnings per share of&nbsp;$0.39&nbsp;to&nbsp;$0.42, and adjusted diluted net earnings per share of&nbsp;$0.83&nbsp;to&nbsp;$0.86.

Earnings

Fortive Q1 Guidance: Expects Revenue Of ~$1.48B-$1.51B Vs. $1.565B Est.; Sees Adjusted EPS Between $$0.83-$0.86 Vs. $0.91 Est.

Barrington Research analyst Patrick Sholl maintains Lions Gate Enter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) with a Outperform and maintains $12 price target.

Lions Gate Entertainment Corporation Class A Voting Shares

LGF/A

Barrington Research Maintains Outperform on Lions Gate Enter, Maintains $12 Price Target

The earnings results for Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) for Q4 were made public on Friday, February 7, 2025 at 07:03 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Plains GP Holdings missed estimated earnings by -111.00000000000001%, reporting an EPS of $-0.05 versus an estimate of $0.46.
Revenue was down $296.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
In the previous quarter, the company missed on EPS by $0.12, resulting in a 3.0% drop change in the share price the following day.
Here's a look at Plains GP Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.29</td>
<td>0.29</td>
<td>0.28</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.17</td>
<td>0.20</td>
<td>0.21</td>
<td>0.27</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>13.11B</td>
<td>12.35B</td>
<td>12.79B</td>
<td>11.91B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.74B</td>
<td>12.93B</td>
<td>11.99B</td>
<td>12.70B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Plains GP Holdings <a href="https://www.benzinga.com/quote/PAGP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAGP

Plains GP Holdings Earnings Review: Q4 Summary

The earnings results for Banco Santander Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSAC#NYSE">BSAC</a>) for Q4 were made public on Friday, February 7, 2025 at 07:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Banco Santander Chile missed estimated earnings by -16.0%, reporting an EPS of $0.59 versus an estimate of $0.7.
Revenue was up $169.57 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company missed on EPS by $0.09 in the previous quarter, leading to a 1.0% drop share price change the next day.
Here's a look at Banco Santander Chile's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.67</td>
<td>0.49</td>
<td>0.36</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.58</td>
<td>0.49</td>
<td>0.26</td>
<td>0.43</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>723.81M</td>
<td>685.66M</td>
<td>614.81M</td>
<td>627.37M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>593.73M</td>
<td>534.55M</td>
<td>500.85M</td>
<td>414.03M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Banco Santander Chile <a href="https://www.benzinga.com/quote/BSAC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSAC

Banco Santander Chile Q4 Earnings Report: What Investors Need to Know

For the full year 2025, Fortive anticipates revenue of approximately $6.23 billion to $6.35 billion, diluted net earnings per share of $2.38 to $2.50, and adjusted diluted net earnings per share of $4.00 to $4.12. The
For the full year 2025, Fortive anticipates revenue of approximately $6.23 billion to $6.35 billion, diluted net earnings per share of $2.38 to $2.50, and adjusted diluted net earnings per share of $4.00 to $4.12. The foregoing guidance for the full year 2025 does not give effect to the pending separation of the Precision Technologies segment.

Fortive Provides 2025 Guidance: Expects Revenue Of $6.23B-$6.35B Vs. $6.488B Est.; Sees Adjusted EPS Between $4-$4.12 Vs. $3.85 Est.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) with a Buy and maintains $1.5 price target.

Reiteration

XFOR

HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target

Barrington Research analyst Gary Prestopino maintains Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) with a Outperform and maintains $12 price target.

CTLP

Barrington Research Maintains Outperform on Cantaloupe, Maintains $12 Price Target

Needham analyst Tom Nikic reiterates Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) from Hold to Hold.

Needham Reiterates Hold on Skechers USAto Hold

iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) saw its shares rise in premarket trading on Friday following the release of its viewership data and content trends for the Chinese New Year holiday period, spanning <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">from January 28 to February 4.</a>
The company said that the platform&#8217;s performance was driven by the popularity of classic IPs, including blockbuster films, which fueled a surge in online viewership and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43555947/iqiyi-sees-surge-in-viewership-during-chinese-new-year-users-favor-classic-ips-long-and-short-cont" rel="noreferrer noopener">overall platform engagement.</a>
In addition, increasing content diversity, such as long-form videos and mini-dramas, captivated audiences, highlighting evolving content preferences.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, IQ stock has lost over 32% in the past year.
Variety shows played a significant role, with iQIYI&#8217;s variety show channel seeing the highest viewing time during the holiday.
The 2025 Spring Festival Gala, produced by China Media Group, maintained its top position in the variety show rankings.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/02/43543297/xrp-down-26-in-7-days-whats-going-on" rel="noreferrer noopener">XRP Down 26% In 7 Days: What&#8217;s Going On?</a>
iQIYI International experienced a 135% year-on-year increase in average viewing time per user for the global livestream. The platform&#8217;s original variety shows also gained strong traction, such as the travel-themed &#8220;The Blooming Journey&#8221; and comedy hits like &#8220;The King of Stand-Up Comedy&#8221; and &#8220;Super Sketch Show.&#8221;
Premium dramas also resonated with viewers, with series like The White Olive Tree, Moonlight Mystique, and Unbreakable 2 dominating content rankings. Notably, Unbreakable 2 sparked renewed interest in its predecessor, leading to a boost in Season 1&#8217;s viewership.
Mini-dramas also gained popularity, with over 70% of their audience aged 35 and below, the company said.
Sequel films, such as Ne Zha 2 and Legends of the Condor Heroes: The Gallants, drove strong viewership for earlier related films and content. iQIYI also saw a boost in animation and kids&#8217; content, including How Dare You!?, PAW Patrol, and Peppa Pig.
Engagement was enhanced through interactive features, including a 118% year-on-year increase in bullet comments and AI-powered chats with fictional characters.
The launch of VR immersive theater experiences also saw significant growth, with a 206% increase in visitor numbers, contributing to the platform&#8217;s successful holiday period.
Price Action: IQ shares are trading higher by 2.58% to $2.39 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43545590/amazoncom-q4-earnings-highlights-revenue-beat-eps-beat-most-successful-holiday-shopping-season-in-company-history" target="_blank" rel="noreferrer noopener">Amazon.com Q4 Earnings: Jassy Highlights &#8216;Successful&#8217; Holiday Season, Q1 Guidance Disappoints Investors</a></li>
</ul>
Image via Shutterstock.

Equities

Movers

General

Why Is iQIYI Stock Gaining Today?

Barrington Research analyst Patrick Sholl maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Outperform and maintains $29 price target.

QNST

Barrington Research Maintains Outperform on QuinStreet, Maintains $29 Price Target

HC Wainwright &amp; Co. analyst Ed Arce reiterates Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) with a Buy and maintains $13 price target.

GNFT

HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

2025 Fiscal&nbsp;Year Financial Guidance
Cboe provided guidance for the 2025&nbsp;fiscal year as noted below.
<ul>
<li>Organic total net revenue growth is expected to be in the mid single digit range in 2025.</li>
<li>Organic net revenue growth from Data Vantage is expected to be in the mid to high single digit range in 2025.</li>
<li>Adjusted operating expenses in 2025 are expected to be in the range of $837 to $852 million. The guidance excludes the expected amortization of acquired intangible assets of $70 million; the company adjusts for this amount in its non-GAAP reconciliation.</li>
<li>Depreciation and amortization expense for 2025 is expected to be in the range of $55 to $59 million, excluding the expected amortization of acquired intangible assets.</li>
<li>The effective tax rate on adjusted earnings for the full year 2025 is expected to be in the range of 28.5 to 30.5 percent. Significant changes in trading volume, expenses, tax laws or rates and other items could materially impact this expectation.</li>
<li>Capital expenditures for 2025 are expected to be in the range of $75 to $85 million.</li>
</ul>

CBOE

Cboe Global Markets Expects FY25 Organic Net Revenue Growth Of Mid-Single-Digit, Capex Of $75M-$85M

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with a Buy and maintains $45 price target.

ORKA

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target

Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.12 by 4.46 percent. This is a 19.39 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $1.620 billion which missed the analyst consensus estimate of $1.624 billion by 0.22 percent. This is a 2.27 percent increase over sales of $1.584 billion the same period last year.

Earnings Beats

Earnings Misses

Fortive Q4 2024 Adj. EPS $1.17 Beats $1.12 Estimate, Sales $1.620B Miss $1.624B Estimate

Cboe Global Markets Q4 2024 Adj. EPS $2.10 Misses $2.11 Estimate, Sales $524.500M Miss $525.880M Estimate

ELF: -27% &#x7C; <a href="https://www.benzinga.com//node/43557152">e.l.f. Beauty shares are trading lower after the company issued FY25 guidance below estimates. Multiple analysts downgraded the stock following the earnings report.</a>
&nbsp;
PINS: 28% &#x7C; <a href="https://www.benzinga.com//node/43556996">Pinterest shares are trading higher after the company reported better-than-expected Q4 revenue results and issued Q1 revenue guidance with its midpoint above estimates.</a>
&nbsp;
DOCS: 26% &#x7C; D<a href="https://www.benzinga.com//node/43556987">oximity shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 and FY25 guidance above estimates.</a>

Trading Ideas

DOCS

PINS

Market-Moving News for February 7th

Telsey Advisory Group analyst Dana Telsey maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $265 to $315.

Telsey Advisory Group Maintains Outperform on Ralph Lauren, Raises Price Target to $315

Warning: LIPO is at high risk of performing badly

Lipella Pharmaceuticals announces 1-for-8 reverse stock split

19:50 EST Lipella Pharmaceuticals (LIPO) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-mov...

Lipella Pharmaceuticals Inc trading halted, news pending

Lipella Pharmaceuticals, Inc. (LIPO) has disclosed a new risk, in the Share Price & Shareholder Rights category. Lipella Pharmaceuticals, Inc. is f...

Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Lipella Pharmaceuticals, Inc. (LIPO – Research Report). ...

Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)

Lipella Pharmaceuticals (LIPO) announced the publication of a peer-reviewed paper in CUREUS. Titled "Rationale for the Use of Topical Calcineurin I...

Comments

Lipella Pharmaceuticals

뉴스

에 대한 최신 뉴스 Lipella Pharmaceuticals (NASDAQ:LIPO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌